These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37161050)

  • 1. Anti-human-TIGIT agonistic antibody ameliorates autoimmune diseases by inhibiting Tfh and Tph cells and enhancing Treg cells.
    Kojima M; Suzuki K; Takeshita M; Ohyagi M; Iizuka M; Yamane H; Koga K; Kouro T; Kassai Y; Yoshihara T; Adachi R; Hashikami K; Ota Y; Yoshimoto K; Kaneko Y; Morita R; Yoshimura A; Takeuchi T
    Commun Biol; 2023 May; 6(1):500. PubMed ID: 37161050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TX99 Is a Neutralizing Monoclonal Antibody Against Mouse TIGIT.
    Nakamura Y; Naito K; Yamashita-Kanemaru Y; Komori D; Hirochika R; Shibuya A; Shibuya K
    Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):105-109. PubMed ID: 29648914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The TIGIT/CD226 axis regulates human T cell function.
    Lozano E; Dominguez-Villar M; Kuchroo V; Hafler DA
    J Immunol; 2012 Apr; 188(8):3869-75. PubMed ID: 22427644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral TIGIT+ T Follicular Helper Cells That Produce High Levels of Interleukin-21
    Akiyama M; Suzuki K; Yoshimoto K; Yasuoka H; Kaneko Y; Takeuchi T
    Front Immunol; 2021; 12():651357. PubMed ID: 33936071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma.
    Yang ZZ; Kim HJ; Wu H; Jalali S; Tang X; Krull JE; Ding W; Novak AJ; Ansell SM
    Clin Cancer Res; 2020 Oct; 26(19):5217-5231. PubMed ID: 32631956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
    Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agonistic anti-TIGIT treatment inhibits T cell responses in LDLr deficient mice without affecting atherosclerotic lesion development.
    Foks AC; Ran IA; Frodermann V; Bot I; van Santbrink PJ; Kuiper J; van Puijvelde GH
    PLoS One; 2013; 8(12):e83134. PubMed ID: 24376654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of TIGIT on CD4+ T cells ameliorates immune-mediated bone marrow failure of aplastic anemia.
    Zhang T; Wang J; Zhou X; Liang R; Bai Q; Yang L; Gu H; Gao G; Dong B; Zhu H; Chen X
    J Cell Biochem; 2014 Nov; 115(11):1918-27. PubMed ID: 24905442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNAM-1 regulates Foxp3 expression in regulatory T cells by interfering with TIGIT under inflammatory conditions.
    Sato K; Yamashita-Kanemaru Y; Abe F; Murata R; Nakamura-Shinya Y; Kanemaru K; Muratani M; Veillette A; Goto M; Ito M; Shibuya A; Shibuya K
    Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34011606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIGIT enhances CD4
    Chen F; Xu Y; Chen Y; Shan S
    Cancer Med; 2020 May; 9(10):3584-3591. PubMed ID: 32212317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226.
    Fuhrman CA; Yeh WI; Seay HR; Saikumar Lakshmi P; Chopra G; Zhang L; Perry DJ; McClymont SA; Yadav M; Lopez MC; Baker HV; Zhang Y; Li Y; Whitley M; von Schack D; Atkinson MA; Bluestone JA; Brusko TM
    J Immunol; 2015 Jul; 195(1):145-55. PubMed ID: 25994968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
    Shibuya A; Shibuya K
    Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody.
    Shirasuna K; Koelsch G; Seidel-Dugan C; Salmeron A; Steiner P; Winston WM; Brodkin HR; Nirschl CJ; Abbott S; Kinugasa F; Sugahara S; Ohori M; Takeuchi M; Hicklin DJ; Yoshida T
    Cancer Treat Res Commun; 2021; 28():100433. PubMed ID: 34273876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating TIGIT
    Luo Q; Xiao Q; Zhang L; Fu B; Li X; Huang Z; Li J
    Heliyon; 2024 Mar; 10(6):e27687. PubMed ID: 38515720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation.
    Han JH; Cai M; Grein J; Perera S; Wang H; Bigler M; Ueda R; Rosahl TW; Pinheiro E; LaFace D; Seghezzi W; Williams SMG
    Front Immunol; 2020; 11():573405. PubMed ID: 33117369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis.
    Yu Y; Chen Z; Wang Y; Li Y; Lu J; Cui L; Yu Z; Ding Y; Guo C; Zhang X; Shi Y
    Int Immunopharmacol; 2021 Jul; 96():107722. PubMed ID: 33965878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between TIGIT
    Lee DJ
    Int Immunopharmacol; 2020 Jun; 83():106378. PubMed ID: 32172208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.
    Chen X; Xue L; Ding X; Zhang J; Jiang L; Liu S; Hou H; Jiang B; Cheng L; Zhu Q; Zhang L; Zhou X; Ma J; Liu Q; Li Y; Ren Z; Jiang B; Song X; Song J; Jin W; Wei M; Shen Z; Liu X; Wang L; Li K; Zhang T
    Front Immunol; 2022; 13():828319. PubMed ID: 35273608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Remission of Sight-Threatening Non-Infectious Uveitis Is Characterized by an Upregulation of Peripheral T-Regulatory Cell Polarized Towards T-bet and TIGIT.
    Gilbert RM; Zhang X; Sampson RD; Ehrenstein MR; Nguyen DX; Chaudhry M; Mein C; Mahmud N; Galatowicz G; Tomkins-Netzer O; Calder VL; Lightman S
    Front Immunol; 2018; 9():907. PubMed ID: 29774027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity.
    Dixon KO; Schorer M; Nevin J; Etminan Y; Amoozgar Z; Kondo T; Kurtulus S; Kassam N; Sobel RA; Fukumura D; Jain RK; Anderson AC; Kuchroo VK; Joller N
    J Immunol; 2018 Apr; 200(8):3000-3007. PubMed ID: 29500245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.